Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
18 Nov, 25
The ESI obesity management guidelines are based on the fast-changing obesity epidemiology & pharmacological options. The novel concepts in the psycho-social aspects & medication counselling of obesity management have also been explored.
18 Nov, 25
The prevalence of obesity has been increasing rapidly in India as well as globally. The clinical practice guidelines from the Endocrine Society of India (ESI) guide the healthcare providers on optimizing the management of obesity.
27 Nov, 25
Diabetes Obes Metab.
- As per network meta analysis of 26 RCTs (143,296 T2DM patients with CKD) vs other antidiabetic medications, SGLT2 inhibitors were most effective in reducing renal outcomes (P score 0.94), eGFR decline >40%/RRT (0.99), MACE (0.93) & HF (1.00)
- GLP 1 RA reduced MI (0.87), macroalbuminuria (0.86) & stroke (0.83)
- Both SGLT2i & GLP 1 RA lowered all cause mortality (0.83), while DPP 4i offered limited benefit.
27 Nov, 25Cureus.
- N=209; Acute respiratory infections (ARIs) in <5 yrs: 59.8% viral (HRV 21%, RSV 16%), 45.5% bacterial (H. influenzae 11%)
- Co-infections: viral 6.7% (HRV-RSV most common), bacterial 8.6% (mostly S. pneumoniae and H. influenzae)
- Peaks: viral post-monsoon, bacterial monsoon
- ARI showed higher odds of bacterial etiology (OR 1.04, P = 0.87), whereas serious ARI (SARI) showed higher odds of viral (OR 0.65, P = 0.04)
26 Nov, 25Ann Intensive Care.
- Carbapenem-resistant Acinetobacter baumannii bloodstream infections (CRAB-BSI) in critically ill were at 56.5% risk of 28-day mortality
- Colistin-based therapy improved survival (HR 0.56-0.59) in patients with higher SOFA scores and non-pneumonia infections
- Sulbactam-based therapy was beneficial (HR 0.37) in pneumonia-related CRAB-BSIs
- Carbapenem- and tigecycline-based regimens offered no benefit.
25 Nov, 25BMC Infect Dis.
- Fluconazole achieved 82.7% (N=374) success in pulmonary cryptococcosis
- In 34 failures, 19 continued fluconazole and 15 switched to voriconazole
- On day 60, voriconazole showed higher response (66.7% vs 15.8%, p=0.002) indicating superior short-term efficacy but long-term (day 180) rates were similar (66.7% vs 68.4%, p=0.914)
- Adverse events were comparable (20% vs 15.8%; p = 0.439)
19 Nov, 25
Featured
4 Nov, 25
Slide Library
30 Oct, 25
30 Oct, 25
Our Research
29 Oct, 25
29 Oct, 25
